key: cord-0761507-z57vcls3
authors: Corpetti, Chiara; Del Re, Alessandro; Seguella, Luisa; Palenca, Irene; Rurgo, Sara; De Conno, Barbara; Pesce, Marcella; Sarnelli, Giovanni; Esposito, Giuseppe
title: Cannabidiol inhibits SARS‐Cov‐2 spike (S) protein‐induced cytotoxicity and inflammation through a PPARγ‐dependent TLR4/NLRP3/Caspase‐1 signaling suppression in Caco‐2 cell line
date: 2021-10-12
journal: Phytother Res
DOI: 10.1002/ptr.7302
sha: 3732a2bec64585bd7b234a53a57f8759e6e5e02e
doc_id: 761507
cord_uid: z57vcls3

Given the abundancy of angiotensin converting enzyme 2 (ACE‐2) receptors density, beyond the lung, the intestine is considered as an alternative site of infection and replication for severe acute respiratory syndrome by coronavirus type 2 (SARS‐CoV‐2). Cannabidiol (CBD) has recently been proposed in the management of coronavirus disease 2019 (COVID‐19) respiratory symptoms because of its anti‐inflammatory and immunomodulatory activity exerted in the lung. In this study, we demonstrated the in vitro PPAR‐γ‐dependent efficacy of CBD (10(−9)‐10(−7) M) in preventing epithelial damage and hyperinflammatory response triggered by SARS‐CoV‐2 spike protein (SP) in a Caco‐2 cells. Immunoblot analysis revealed that CBD was able to reduce all the analyzed proinflammatory markers triggered by SP incubation, such as tool‐like receptor 4 (TLR‐4), ACE‐2, family members of Ras homologues A‐GTPase (RhoA‐GTPase), inflammasome complex (NLRP3), and Caspase‐1. CBD caused a parallel inhibition of interleukin 1 beta (IL‐1β), IL‐6, tumor necrosis factor alpha (TNF‐α), and IL‐18 by enzyme‐linked immunosorbent assay (ELISA) assay. By immunofluorescence analysis, we observed increased expression of tight‐junction proteins and restoration of transepithelial electrical resistance (TEER) following CBD treatment, as well as the rescue of fluorescein isothiocyanate (FITC)–dextran permeability induced by SP. Our data indicate, in conclusion, that CBD is a powerful inhibitor of SP protein enterotoxicity in vitro.

functional subunits, responsible for binding the host cell ACE-2 receptor (S1 subunit) and fusion of viral and cell membranes (subunit S2) (Walls et al., 2020) .

In addition to its prominent pathological manifestations at respiratory and vascular level, digestive symptoms, ranging from nausea to diarrhea, have been highlighted during COVID-19 (Esposito, Pesce, Seguella, Sanseverino, Lu, Sarnelli, 2020b; Kopel et al., 2020) , leading to consider the digestive tract as a potential route of infection (Zhang et al., 2020) . Likewise, it has been described for other members of the coronaviridae family, SARS-CoV-2 is able to colonize intestinal tissue and, considering the high distribution of the ACE-2 receptors in the epithelial intestinal mucosa, to actively replicate into the gut, making this body district a crucial biological niche for SARS-CoV-2 hosting and expansion toward the respiratory and cardiovascular system (Dickson I., 2020) . In addition, recent studies highlighted the ability of SARS-CoV-2 SP to interact with TLR-4 triggering an inflammatory response in both human and murine alveolar macrophages, suggesting an active role of this protein in hyperinflammatory conditionobserved COVID-19 patients Zhao et al., 2021) .

Despite such evidence, the effects of the SARS-CoV-2 SP on the intestinal epithelial cells, on the integrity of the mucosa and its role in inflammation, are still not clearly investigated. Furthermore, as demonstrated in macrophages and in lung epithelia, SARS-CoV-2 SP can induce a proinflammatory response in infected cells by triggering inflammasome NLRP3 complex activation (Sebastian et al., 2021) .

NLRP3 protein, as part of pattern recognition receptors (PRR), is a NOD-like receptor containing the pyrin effector domain able to trigger and participate in inflammasome formation (Kelley et al., 2019) .

During SARS-CoV-2 infection, this pathway is hyperactivated, leading to an aberrant release of cytokines and other proinflammatory molecules at the root of cellular pyroptosis, and consequent cytokine storm that features poor prognosis in COVID-19 patients. The identification of immunomodulatory and anti-inflammatory compounds able to reduce NLRP3 activation triggered by SARS-CoV-2 SP can be regarded with particular interest especially at intestinal epithelium level. Moreover, it has been shown that the reduction of Ras homolog family members, A-GTPases (RhoA GTP) with the subsequent destruction of mosaic-like organization of the intestinal epithelium, is able to trigger the activation of NLRP3/Caspase-1/IL-1β and IL-18 pathway (Park et al., 2016) . Considering the well-established "gate-keeper" properties of CBD due to its ability to rescue RhoA GTPase (Gigli et al., 2017) , we proposed it as a possible molecule able to downregulate NLRP3/Caspase-1/IL-1β and IL-18 pathway.

CBD is a nonpsychoactive cannabinoid from Cannabis sativa exerting different pharmacological activities ranging from antioxidant and anti-inflammatory to neuroprotective and immunomodulatory effects (De Filippis et al., 2011; Izzo & Sharkey, 2010) . Unlike psychoactive cannabinoids such as tetrahydrocannabinol (THC), CBD does not show significant affinity to cannabinoid receptors (either CB1 and CB2), whereas, by acting on PPAR-γ (O'Sullivan & Kendall, 2010) and 5-hydroxytryptamine (5HT)-1A receptors (Mishima et al., 2005) , it displays anti-inflammatory and antioxidant effects. Aside to its potent anti-inflammatory activity in the gut, acting at PPAR-γ site, CBD has shown the ability to markedly recover epithelial mucosal damage induced various stimuli ranging from clostridium difficile toxin A (TcdA) (Gigli et al., 2017) to ethylenediaminetetraacetic acid (EDTA) (Alhamoruni et al., 2010) and others proinflammatory stimuli.

Although CBD's well-known anti-inflammatory and immunoregulatory activities have candidate it as a potential drug in the treatment of acute respiratory distress syndrome (ARDS) following COVID-19 infection (Bifulco et al., 2021; Nagarkatti et al., 2020) , it is a possible protective effect, as well as the role of SARS-CoV-2 SP at the level of the intestine epithelium, remains obscure. To this aim, the present study focuses on investigating the effect of SARS-CoV-2 SP on NLRP3 inflammasome pathway activation and relative molecular mechanisms responsible for SARS-CoV-2 SP-induced cytotoxic damage on cultured Caco-2 cells.

Caco-2 cell line was obtained from the European Collection of Cell Cultures (ECACC, Public Health England Porton Down, Salisbury, UK). Cell culture medium, fluorescein isothiocyanate (FITC)-dextran, size 4 kDa, and 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, Missouri). The SP from SARS-CoV-2 (recombinant human novel coronavirus spike glycoprotein(S), partial (active)) was purchased by Cusabio (Wuhan, China); the purity is greater than 90%, 4 0 ,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific Inc., Waltham, Massachusetts), fluorescein isothiocyanate-conjugated antirabbit antibody, and Texas red conjugated antimouse antibody were from Abcam (Cambridge, UK). CBD, the purity of which is greater than 98%, and PPAR-γ antagonist (GW9662) were purchased from Tocris Cookson, Inc. (Ballwin, Missouri). All the technical support instruments, reagents, and materials for transepithelial electrical resistance (TEER) (Merck KGaA, Darmstadt, Germany), electrophoresis, and western blot analysis were obtained from Bio-Rad (Bio-Rad Laboratories, Milan, Italy). Rabbit anti-ZO-1 and rabbit anti-TLR4 were obtained from Bioss (Bioss Antibodies, Boston), and mouse antioccludin antibody was obtained from Novus Biologicals (Minneapolis)(see Table 1 ,2). Mouse antiglyceraldheyde-3-phosphate dheydrogenase (GAPDH), mouse anti-RhoA-GTPase, and mouse anti-ACE-2 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, California); rabbit anti-NLRP3 and rabbit anti-Caspase-1 were obtained from Invitrogen (Invitrogen; Thermo Fisher Scientific, Inc. Monza, Italy) (see Table 1 ). Enhanced chemiluminescence detection reagents were from Amersham Biosciences (Milan, Italy), and horseradish peroxidase (HRP) was obtained from Dako (Milan, Italy). The level of TNFɑ, IL-6, IL-1β, and IL-18 was measured using ELISA (Section 2.7) kits.

Caco-2 cells were cultured in 6-well plates in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, 2 mM L-glutamate, and 1% nonessential amino acids. A total of 1 Â 10 6 cells/well was plated and incubated, and both undifferentiated and differentiated cells (the apical tract for TEER) were obtained at different times, depending on the assay. Cells were washed three times with phosphate-buffered saline (PBS), detached with trypsin/ethylene diamine tetraacetic acid (EDTA), and dependently on the experiment plated in 6-well plates, 96-well plates, or 10 cm diameter Petri dish and allowed to adhere for further 24 h.

The Caco-2 cells were randomly divided into eight groups: 1) vehicle group, 2-4) 0.1, 1, 10 ng/ml SP group, 5-7) 10 ng/ml SP plus 10 À9 , 10 À8 , 10 À7 M CBD, and 8) 10 ng/ml SP with 10 À7 M CBD plus 9 nM GW9662 antagonist PPAR-γ. Cells were treated with SARS-CoV-2 SP dissolved in ultrapure and pyrogen-free sterile vehicle for 24 h. SP concentrations were previously selected by pilot experiment aimed at identifying the lowest effective concentration (data not shown). CBD and GW9662 were selected according to the results of previous published research (Sarnelli G. et al., 2016) .

The TEER of the Caco-2 cell monolayer was determined using the EVOM volt-ohm meter (World Precision Instruments Germany, Berlin, Germany) according to the method previously described (Wells et al., 1998) . In brief, cells plated between 14 and 21 days were used, and epithelial cell layers with a TEER value greater than 1,000 Ω/cm 2 were considered to have tight adhesion. TEER values were measured at a current of 20 mA, corrected for background resistance value without cells, and normalized by multiplying the determined resistance by effective membrane growth area, 4.71 cm 2 . TEER (Ω/cm 2 ) = (Total resistance À blank resistance) (Ω) Â Area (cm 2 )

To measure the permeability of cultured Caco-2 monolayer in our experimental conditions, we measured the flux of FITC-dextran method (Wu et al., 2019) . FITC-dextran (1 mg/ml) was then added to upper insets. Cells plated between 14 and 21 days were used; after 6 h of incubation, the basolateral medium aliquots were collected, and the fluorescence was measured at 480-nm excitation and 520-nm emission wavelengths.

The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT reagent) assay was used to determine Caco-2 cell proliferation and survival (Mosmann, 1983) . The cells in DMEM (5 Â 10 4 cells/well) were plated in 96-well plates and allowed to adhere for further 24 h. DMEM was then replaced with fresh medium, and the cells underwent treatments as above described, exposed to SP (0.1-10 ng/ml) alone, the highest concentration in the presence of CBD (10 À9 -10 À7 M) and finally the group with 9 nM GW9662 antagonist for PPAR-γ.

After 24 h, 25 μl of MTT stock solution in DMEM (5 mg/ml) were added to the cells and then incubated for 3 h at 37 C. Subsequently, the cells were lysed, and the dark blue crystals were solubilized using a 100 μl solution containing 50% N,N-dimethylformamide and 20% (w/v) sodium dodecyl sulphate (SDS) (pH 4.5). The optical density (OD) of each well was determined using a microplate spectrophotometer equipped with a 620 nm filter (PerkinElmer, Inc.; Waltham, Massachusetts).

The Caco-2 undifferentiated cells were grown on glass coverslip (5 Â 10 4 cells/well) and incubated for 24 h with DMEM; the medium was replaced with fresh medium, and the cells underwent treatments as described above. Cells were fixed with 4% PFA for 10 min and followed by three-time washing with ice-cold PBS 1X. Nonspecific binding sites were blocked by 2% bovine serum albumin (BSA). The presence of pyroptotic cells was also shown with DAPI staining. The cells were incubated with DAPI (1:50000 v/v) for 10 min and washed with PBS. The pyroptotic cells were analyzed using an inverted 

Protein expression in Caco-2 cells was evaluated using Western blot analysis. Following treatments, undifferentiated cells ( (Table 1) . Membranes were then incubated with the specific secondary antibodies conjugated to HRP. Immune complexes were exposed to enhanced chemiluminescence detection reagents, and the blots were analyzed by scanning densitometry (Versadoc MP4000; Bio-Rad, Segrate, Italy). Results were expressed as optical density (OD; arbitrary units = mm 2 ) and normalized against the expression of the housekeeping protein GAPDH.

For these experiments, undifferentiated Caco-2 cells were cultured onto coverslips until confluence and divided into four groups: 1) Vehicle, 2) 10 ng/ml SP, 3) 10 ng/ml SP plus 10 À7 M CBD, and 4) 10 ng/ml SP with 10 À7 M CBD plus 9 nM GW9662 antagonist PPAR-γ. Cells were then fixed for 10 min in 4% formaldehyde, washed with ice-cold PBS and permeabilized with 0.3% Triton-X100 in PBS for 15 min.

Subsequently, 2% BSA was used to block the nonspecific binding sites. The cells were then incubated overnight with mouse monoclonal anti-ZO-1 (1:100 v/v) or rabbit polyclonal antioccludin antibody 

Results are expressed as the mean ± SD of the mean of n = 6 experiments in triplicate. Statistical analyses were performed using unpaired t-test and one-way analysis of variance (ANOVA), and multiple comparisons were performed using a Bonferroni post-hoc test. p < 0.05, p < 0.01, and p < 0.001 was considered to indicate a statistically significant difference.

3 | RESULTS

The incubation with increasing concentration (0.1-10 ng/ml) of SP caused a concentration-dependent decrease of cell viability (À21%, À47%

and À72% vs. vehicle group, respectively) at 24 h in cultured Caco-2 cells by MTT analysis (Figure 1a ). In the same experimental condition, SP promoted a parallel formation of pyroptotic bodies, increasing chromatin thickening in the cell nuclei (+307%, +603%, +826% vs. vehicle group) (Figure 1b,c) . In the presence of CBD (10 À9 -10 À7 M), a significant and concentration-dependent rescue of cell viability was obtained (+31, +110% and +214% vs. SP 10 ng/ml group), respectively ( Figure 1a ). In parallel with this, cannabidiol also induced a significant reduction of condensed nuclei (À20%, À36%, À68% vs. SP 10 ng/ml group) (Figure 1b,c) . Interestingly, in the presence of PPAR-γ antagonist 3.2 | Cannabidiol reduces spike protein-induced ACE-2 expression and inhibits inflammasome pathway by modulating TLR4/NLRP3 protein through a PPAR-γ involvement

Following 24 h SP (0.1-10 ng/ml) incubation, a significant and concentration-dependent increase of TLR4 (+52%, +207%, +451%

vs. vehicle, respectively) and ACE-2 protein expression in Caco-2 in cellular membrane homogenates was observed (+42%, +102%, +259% vs. vehicle, respectively). While on the contrary, SP caused a marked decrease of RhoA GTP (À30%, À55%, À84% vs. vehicle group, respectively) in the cytoplasmic cellular portion of Caco-2 ( Figure 2a-d) . In parallel with these results, SP also increased NLRP3 (+80%, +264%, and +494% vs. vehicle group, respectively) and

Caspase-1 (+111%, +365% and +809% vs. vehicle, respectively) cytoplasmic protein expression in Caco-2 homogenates (Figure 2a , e, f). CBD effect resulted in a significant and concentration-dependent inhibition of both TLR4 (À28%, À41%, À76% respectively vs. SP 10 ng/ml group) and ACE-2 protein expression (À25%, À38.4%, and À57% vs. SP 10 ng/ml group) paralleled to a marked rescue of RhoA GTP (+83%, +365% and +490% vs. SP 10 ng/ml) expression ( Figure 2a-d) . Notably, CBD effect was thus accompanied to a significant and concentration-dependently inhibition of both NLRP3 (À22.6%, À48% and À72% vs. SP 10 ng/ml group, respectively) and

Caspase-1 (À22%, À49%, À74% vs. SP 10 ng/ml group, respectively) protein expression induced by SP challenge (Figure 2a , 3.3 | CBD decreases TNF-α, IL-6, IL-1β, and IL-18 release in SP-challenged Caco-2 cells

As a consequence of proinflammatory signaling pathway activation, SP (0.1-10 ng/ml) challenge resulted in a marked increase of TNF-α (+125%, +213%, +400% vs. vehicle group, respectively), IL-6 (+144%, +217%, +337% vs. vehicle group, respectively), IL-1β (+167%, +257%, +448% vs. vehicle group, respectively, and IL-18(+203%, +303%, +502% vs. vehicle group, respectively) secretion in Caco-2 cell

Caco-2 cells exposed to spike protein (SP) (0.1-10 ng/ml) in the presence of CBD (10 À9 -10 À7 M) in the presence/absence of PPAR-γ antagonist GW9662 (9 nM) at 24 h; (b) immunofluorescence microphotographs showing 4 0 ,6-diamidino-2-phenylindole (DAPI) staining of Caco-2 cell nuclei exposed to SP (0.1-10 ng/ml) in the presence of CBD (10 À9 -10 À7 M); and (c) quantification of the relative proportion (%) of apoptotic nuclei evidenced by chromatin aggregates (indicated by white arrows). Magnification 20Â (scale bar, 20 μm). Results are expressed as mean ± standard deviation (SD) of n = 4 experiments performed in triplicate. ***p < 0.001 **p < 0.01 and *p < 0.05, respectively, versus vehicle; p < 0.001, p < 0.01, and p < 0.05, respectively, versus SP 10 ng/ml [Colour figure can be viewed at wileyonlinelibrary.com] supernatant at 24 h (Figure 3a-d) . Such observed release of proinflammatory cytokines was concentration-dependently mitigated by CBD (10 À9 -10 À7 M) incubation, that resulted in a marked decrease of TNF-α (À28%, À46%, and À66% vs. SP 10 ng/ml group, respectively), IL-6 (À18%, À33%, and À65% vs. SP 10 ng/ml group, respectively), IL-1β (À28%, À51.2% and À69% vs. SP 10 ng/ml group, respectively), and IL-18 (À29%, À49.5%, À68.10% vs. SP 10 ng/ml group, respectively) release in cell medium, reinforcing the evidence for its anti-inflammatory effect in vitro. As expected, in the presence of PPAR-γ antagonist GW9662 (9 nM), CBD (10 À7 M) incubation did not reach any significant inhibitory effect of SARS-CoV-2 SP-induced proinflammatory cytokine release in the same experimental conditions (Figure 3a-d) .

Following SP challenge (10 ng/ml), a significant and time-dependent reduction of TEER was observed starting from 3 h and in the subsequent time intervals at 6, 9, 12, 15, 18, 21, and 24 h in confrontation with the vehicle group. TEER values were progressively decreased in the time by À24.2%, À33%, À50%, À64%, À78%, À80%, À81%, and À89%, respectively, versus the vehicle group (Figure 4a ). In the presence of highest CBD at highest concentration (10 À7 M), a significant rescue (+44%, +85%, +151%, +291%, +330% +363%, and +727%, respectively, versus SP 10 ng/ml group, respectively) of TEER was observed starting at 6 h in the same interval time (Figure 4a ). In agreement with these results, SP (0.1-10 ng/ml) stimulus, caused a concentration-dependent increase of FITC-dextran flux in cultured cells as marker of cell permeability (+116%, +285%, +411%

vs. vehicle group, respectively) ( Figure 4b ). According to TEER, SP effects on FITC-dextran flux were massively and concentrationdependently counteracted by CBD (À17%, À39%, and À50% vs. SP 10 ng/ml group, respectively) ( Figure 4b ). As expected, neither significant recovery of TEER decrease nor FITC-dextran fluxes were obtained in the same experimental conditions when CBD was coincubated with PPAR-γ antagonist GW9662 (9 nM) (Figure 4a, b) . Furthermore, immunofluorescence analysis of tight junction proteins, occludin and ZO-1, was in line with TEER data, since SP stimulus (10 ng/ml) markedly reduced both occludin (À71% vs. vehicle group) and ZO-1 (À72% vs. vehicle group) expression in cultured cells at 

Although the typical manifestations of COVID-19 have been described at the pulmonary and vascular level, many patients infected with SARS-CoV-2 develop gastrointestinal symptoms, such as nausea, vomiting, and diarrhea (Ong & Dan, 2021) .

Nowadays, the role of the ACE-2 receptor as the interaction site between SARS-CoV-2 SP and the host cells is well known. Intestinal epithelium, expressing significant levels of ACE-2 protein, represents a potential site of entry for SARS-CoV-2 that can allow its replication and propagation. Interestingly, the more the SARS-CoV-2 viral infection involves the intestinal epithelium, the more severe the pulmonary and postinfectious consequences of COVID-19 seem to be (Ahlawat & Sharma, 2020) . As well as in the respiratory tract, Car- (Nelson et al., 2020) , CBD might exert a remarkable gate-keeper capacity on the intestinal epithelium (Berg et al., 2021) . This CBD's efficacy in counteracting the induced cell damage and epithelial hyperpermeability has been highlighted in several models, ranging from bacterial toxins (Joffre et al., 2020) to other stimuli (Cocetta et al., 2021) .

Interestingly, we noticed that the reduction of cells viability was almost the same in the group treated with the specific PPAR-γ inhibitor GW9662 (8) and in the one treated with SP ng/ml (4). In parallel, the groups treated with CBD, without GW9662 (5-7), showed a significant and concentration-dependent rescue of cells viability. These experimental outcomes suggested that CBD, acting at the PPAR-γ site, can interfere with inflammasome complex formation, preventing the release of propyroptotic mediators and rescuing cells viability . Moreover, in our experimental conditions, CBD incubation was able to down-regulate the expression of the ACE-2 receptor in Caco-2 cells. Interestingly, a previous study by Anil group observed a similar decrease of the ACE-2 receptor in lung epithelial cells induced by CBD (Anil et al., 2021) . This combined preliminary evidence may suggest that such a molecule could systemically reduce the patient's susceptibility to SARS-CoV-2 infection. Also, patients expressing high ACE-2 density seem to be more susceptible to SARS-CoV-2 and to show worse clinical outcomes. Conversely, healthy patients with much lower activity for this receptor have beneficial anti-inflammatory, antioxidant and antifibrotic effects (Malinowska et al., 2021) . 

The assistance of the staff is gratefully appreciated.

The present experimental work was partially supported by SAPIENZA University Grants n. AR11816433B8F7F8 assigned to Luisa Seguella.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 

The raw data supporting the conclusions of the present manuscript will be made available by the authors, without undue reservation.

Immunological co-ordination between gut and lungs in SARS-CoV-2 infection

Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability

Cannabis compounds exhibit antiinflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages

Cannabidiol enhances intestinal cannabinoid receptor type 2 receptor expression and activation increasing regulatory T cells and reduces murine acute graft-versus-host disease without interfering with the graft-versus-leukemia response

Commentary: Use of cannabinoids to treat acute respiratory distress syndrome and cytokine storm associated with coronavirus disease-2019

Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of COVID-19 patient with diarrhea

COVID-19 vaccines: The status and perspectives in delivery points of view

Cannabidiol isolated from Cannabis sativa L. protects intestinal barrier from in vitro inflammation and oxidative stress

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis

Ultramicronized palmitoylethanolamide inhibits NLRP3 inflammosome expression and pro-inflammatory response activated by SARS-CoV-2 spike protein in cultured murine alveolar macrophages

Organoids demonstrate gut infection by SARS-CoV-2

Specific re-distribution of SARS-CoV-2 variants in the respiratory system and intestinal tract

The potential of cannabidiol in the COVID-19 pandemic

Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion?

Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells

Cannabinoids and the gut: New developments and emerging concepts

Activation of CB(1)R promotes lipopolysaccharide-induced IL-10 secretion by monocytic myeloid-derived suppressive cells and reduces acute inflammation and organ injury

The NLRP3 Inflammasome: An overview of mechanisms of activation and regulation

Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA

Clinical insights into the gastrointestinal manifestations of COVID-19

Opportunities, challenges and pitfalls of using cannabidiol as an adjuvant drug in COVID-19

A systematic review of cannabidiol dosing in clinical populations

Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays

Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism

Use of cannabinoids to treat acute respiratory distress syndrome and cytokine storm associated with coronavirus disease-2019

The essential medicinal chemistry of cannabidiol (CBD)

Cannabidiol inhibits SARS-CoV-2 replication and promotes the host innate immune response. bioRxiv: The Preprint Server for Biology

GI-COVID: Are there COVID-19 patients with primary gastrointestinal SARS-CoV-2 infection and symptoms. Digestive Diseases and Sciences, 1-3, 3228-3230

Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease

Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS

Cannabidiol as a novel therapeutic for immune modulation

Cannabidiol treatment for severe and critical coronavirus (COVID-19) pulmonary infection

Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A(2A) receptor

Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome

Palmitoylethanolamide exerts antiproliferative effect and downregulates vegf signaling in caco-2 human colon carcinoma cell line through a selective ppar-α-dependent inhibition of akt/mtor pathway

Synthetic CBD as a Therapy for COVID-19

A molecular basis for the antiinflammatory and anti-fibrosis properties of cannabidiol

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Cytochalasin-induced actin disruption of polarized enterocytes can augment internalization of bacteria

Paeoniflorin prevents intestinal barrier disruption and inhibits lipopolysaccharide (lps)-induced inflammation in caco-2 cell monolayers

Differentiated Caco-2 cell models in food-intestine interaction study: Current applications and future trends

Inhibitory effect of PPARγ on NLRP3 inflammasome activation

Digestive system is a potential route of COVID-19: An analysis of single-cell coexpression pattern of key proteins in viral entry process

SARS-CoV-2 spike protein interacts with and activates TLR41

Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line